---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-26-000112"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2026-09-21T13:05:27+00:00"
generated_at: "2026-09-21T13:06:12.034224+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Recursion amends Tempus master agreement, grants RNA model license for $12M

## Summary
- Amendment extends Master Agreement term to six years, eliminates termination-for-convenience clause.
- Annual License Fees for years 3-5 revised to $14M each, with at least $4M cash, rest in stock/cash.
- Recursion grants Tempus non-exclusive oncology-only license to TxFM RNA model for 2 years.
- Tempus pays $12M total license fee in two $6M installments; first on execution, second at one-year.
- Tempus provides Recursion access to de-identified pathology records with linked clinical data.

## SEC filing metadata
- accession: 0001601830-26-000112
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2026-09-21T13:05:27+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000112/0001601830-26-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000112/rxrx-20260915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-26-000112
- JSON: https://secwatch.observer/filing/0001601830-26-000112.json
- Plain text: https://secwatch.observer/filing/0001601830-26-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.